The venture capital arm of GlaxoSmithKline, SR One, has co-led a $33 million venture round for the UK's Syntaxin--a developer focused on cell secretion. The Series B was also co-led by Life Science ...

The U.K.'s Syntaxin has gained a $29 million injection of cash with some considerable contributions from the corporate venture crowd. Newcomers Lundbeckfond Ventures, Ipsen and Seventure joined ...

Firm could receive $9 million from Ipsen during first three years of collaboration. Syntaxin could receive up to $9 million from Ipsen during the first three years of a global collaboration to ...

Ipsen said today it will buy drug developer Syntaxin in a deal that could reach more than €158 million ($206 million), three years after the French specialty pharma giant began collaborating ...

Syntaxin, partnered with Allergan, announced the initiation of two Phase 2 studies of AGN-214868 for the treatment of patients with post herpetic neuralgia and overactive bladder. The trials will ...

What’s more, researchers found that vitamin B12 and folate worked to increase the levels of syntaxin 17 and helped reverse the fibrosis (thickening or scarring) and inflammation of the liver.

Syntaxin, a privately-owned UK biotechnology firm developing novel drugs that work by controlling cell secretion, has raised £16 million in a new funding round co-led by SR One, the venture capital ...

Ipsen took two steps forward in its efforts into neurology with the purchase of research partner Syntaxin and an agreement with Harvard Medical School in the US. The French pharma company is set to ...